GlassScriptPhysician profile
Matt Havens
NPI 1992912216
$3,265.63
in general payments reported to CMS, 2019-2025
24 companies · $901 in 2025
The $901 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $366 · 2022: $431 · 2023: $598 · 2024: $969 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $872.86 | 2021-2025 | |
| Abbott Laboratories | $339.09 | 2023-2025 | Freestyle Libre |
| Novo Nordisk INC | $324.01 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $318.47 | 2021-2025 | |
| Lilly USA, LLC | $180.25 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| E.R. Squibb & Sons, L.L.C. | $163.84 | 2025 | Cobenfy |
| Astrazeneca Pharmaceuticals LP | $162.09 | 2021-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $157.35 | 2021-2025 | Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.00 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $104.55 | 2022-2025 | Rexulti, Abilify Maintena |
| Amgen INC. | $94.35 | 2022-2025 | Repatha, Otezla, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.49 | 2021-2023 | Xifaxan |
| Dexcom, INC. | $62.32 | 2021-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $58.53 | 2021-2025 | |
| Exact Sciences Corporation | $57.41 | 2024-2025 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $39.83 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.76 | 2022 | |
| Indivior INC. | $26.50 | 2022 | |
| Organon LLC | $24.84 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $18.13 | 2025 | |
| Phathom Pharmaceuticals, INC. | $16.41 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $15.07 | 2025 | Uzedy |
| Novartis Pharmaceuticals Corporation | $13.59 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matt Havens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.